De novo hypertension after liver transplantation.
Hypertension develops in most patients after transplantation when immunosuppression is based on cyclosporine and prednisone. The pathogenesis appears to be multifactorial but involves rapidly rising vasoconstrictor tone in renal and systemic vascular beds. Much of this tone reflects abnormal vascular function, characterized by impaired prostacyclin and EDRF effects, in conjunction with increased vasoconstriction due to endothelin and possibly other factors. Effective management of the transplant recipient depends on preventing excessive vasoconstriction, usually with calcium channel blocking agents.
Textor
S C
SC
Division of Hypertension, Mayo Clinic, Rochester, Minnesota.
D000328:Adult; D001379:Azathioprine / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000209:etiology*; D007165:Immunosuppression Therapy / Q000009:adverse effects; D007741:Labetalol / Q000627:therapeutic use; D016031:Liver Transplantation; D008297:Male; D009894:Opportunistic Infections / Q000209:etiology; D011182:Postoperative Care; D011183:Postoperative Complications; D011241:Prednisone / Q000627:therapeutic use
D016572:Cyclosporine; D001379:Azathioprine; D007741:Labetalol; D011241:Prednisone